Peptide News Digest

Novo Retires Rybelsus for Ozempic Pill, Wegovy Pill Hits 113K Weekly Scripts, Manchester Penicillin Biosynthesis, Ozempic Face Data, Roche ENITH Phase 3

Novo retires Rybelsus brand for Ozempic Pill, Manchester Nature Comms penicillin biosynthesis, Ozempic Face data, Roche ENITH Phase 3, Wegovy pill hits 113K scripts.

10 stories · Covering industry, research, clinical-trials, regulatory

Editor's Note

The May 1–2 cycle produced two distinct branches of the peptide story. On the GLP-1 commercialization side, Novo Nordisk officially retired the Rybelsus brand in the US and re-launched the same molecule as Ozempic Pill — leaning into the brand recognition of its blockbuster injectable to defend market share against Lilly's small-molecule Foundayo. The IQVIA weekly tracker showed Wegovy pill at roughly 113,000 prescriptions in its most recent reported week, more than 20× Foundayo's Week 3 reading of 5,612. New plastic-surgery and endocrinology data on "Ozempic Face" — a 9% midface volume loss per 10 kg of weight loss, with a 50% surge in face-grafting demand — added a side-effect chapter that GLP-1 prescribers and aesthetic-medicine clinics will both have to manage. Beyond GLP-1s, a Manchester team published an alternative enzymatic pathway to penicillins in Nature Communications using a standalone ligase plus an engineered IPNS, opening a cleaner biosynthetic route to penicillin G, V, and ampicillin — a substantive AMR-adjacent advance. AJMC ran a consumer-grade oral-peptides FAQ that quietly mainstreams the technical conversation ahead of the July PCAC meeting. Roche's Q1 detail clarified that ENITH 1 and ENITH 2 — its enicepatide Phase 3 obesity trials — were initiated in Q1, with the petrelintide combination Phase 2 starting mid-2026. A May 1 bioRxiv preprint extended generative AI peptide design to custom secondary-structure motifs using reduced amino-acid alphabets, a step toward more controllable de novo cyclic peptide drug candidates. The 2026 TIDES USA conference (May 11–14, Boston) and Hims & Hers' May 11 Q1 print loom as the next inflection points.

Industry

Novo Nordisk Officially Retires Rybelsus Brand in US, Re-launches Same Molecule as 'Ozempic Pill' to Tap Blockbuster Recognition

Novo Nordisk announced May 1 that Rybelsus is being retired as a US brand and the molecule re-launches Monday May 4 as Ozempic Pill at 1.5/4/9 mg in 70,000+ pharmacies. Bloomberg and Fierce Pharma framed it as a marketing-driven move: same active ingredient as Rybelsus, but reformulated for improved absorption and bioavailability so smaller tablets achieve equivalent efficacy. Aligning the oral and injectable products under a single brand is meant to simplify prior authorizations and prescribing discussions, and to capitalize on Ozempic's recognition as Novo defends market share against Lilly's Foundayo. Rybelsus continues outside the US.

#novo-nordisk #ozempic-pill #rybelsus #rebrand #oral-semaglutide #glp-1
Industry

Wegovy Pill IQVIA Tracker: ~113,000 US Prescriptions in Latest Week vs. Foundayo's 5,612 — Oral GLP-1 Race Tilts Decisively to Novo Early

IQVIA data cited by Deutsche Bank analysts and Pharmaphorum showed Novo Nordisk's Wegovy pill at roughly 113,354 prescriptions in its most recent reported week, up from 105,366 the week prior. That puts Novo's January-launched oral semaglutide more than 20× ahead of Lilly's Foundayo Week 3 reading of 5,612, and the gap is from US retail-channel data alone — NovoCare Pharmacy direct-to-consumer volumes are additional. Lilly executives have asked analysts to wait 8–12 weeks for a clearer read, but the early Foundayo-versus-Wegovy-pill comparison continues to favor Novo on raw volume.

#wegovy-pill #novo-nordisk #iqvia #foundayo #oral-glp-1 #launch-tracker
Research

Plastic Surgery + Endocrine Data Confirm 'Ozempic Face': 9% Midface Volume Loss per 10 kg, 50% Surge in Face-Grafting Demand

DistilINFO and an Endocrine review published May 1 consolidated the clinical literature on accelerated facial aging in patients on GLP-1 receptor agonists. A 2025 Vanderbilt study reported approximately 9% midface volume loss per 10 kg of total weight loss, with GLP-1-mediated lipolysis disproportionately affecting superficial and medial cheek fat pads. The American Academy of Facial Plastic and Reconstructive Surgery reported a 50% increase in face-grafting procedures in the past year tied to the trend, and one in four surgeons expects continued growth in nonsurgical demand (fillers, microneedling, RF, CO2 laser). Mechanistic work in Endocrine adds a possible direct effect on adipose-derived stem cells beyond rapid fat loss alone.

#ozempic-face #glp-1 #facial-aging #plastic-surgery #lipolysis #side-effects
Research

Nature Communications: Manchester Team Reports Alternative Enzymatic Pathway to Penicillins via Standalone Ligase Plus Engineered IPNS

Saha, Xu, Panda, and Micklefield at the University of Manchester and Manchester Institute of Biotechnology published a Nature Communications paper April 30 describing a fundamentally simpler biosynthetic route to penicillin antibiotics. Instead of the traditional ACV tripeptide assembled by complex non-ribosomal peptide synthetase (NRPS) machinery, the team uses standalone glutathione-style ligase and epimerase enzymes to generate the peptide precursor, then transforms it with an engineered isopenicillin N synthase (IPNS) to produce penicillin G, penicillin V, and ampicillin directly. The pathway sidesteps the semisynthesis steps currently required for these penicillins and could simplify production at scale — material in an AMR landscape where supply economics matter as much as new chemistry.

#penicillin #biosynthesis #ipns #ligase #manchester #nature-communications #antibiotic-manufacturing
Clinical Trials

Roche Q1 2026 Detail: ENITH 1 and ENITH 2 Phase 3 Enicepatide Obesity Trials Initiated in Q1; Petrelintide+Enicepatide Phase 2 Combination Set for Mid-2026

On the April 23 Q1 call and follow-up coverage, Roche clarified that its two Phase 3 enicepatide (CT-388) obesity trials — ENITH 1 and ENITH 2 — were both successfully initiated in Q1, with the dual GLP-1/GIP agonist on track to compete in the next-wave Phase 3 obesity readouts. Phase 2 reported 22.5% placebo-adjusted weight loss for enicepatide. Roche also confirmed the petrelintide+enicepatide fixed-dose combination Phase 2 will dose its first patient around mid-2026, pairing the Zealand-derived amylin analog (placebo-like tolerability, 10.7% mean weight loss in ZUPREME-1 at week 42) with Roche's stronger GLP-1/GIP backbone. Additional Phase 2 readouts for oral GLP-1 CT-996 are guided before year-end 2026.

#roche #enicepatide #ct-388 #enith #petrelintide #ct-996 #phase-3 #obesity
Industry

AJMC Oral Peptides FAQ Mainstreams the Bioavailability and Safety Conversation Ahead of July PCAC

AJMC ran a consumer-grade FAQ on oral peptides covering bioavailability (typically <1% even with optimized formulations), delivery technologies (SNAC for oral semaglutide, liposomal systems, lipidation as in liraglutide and insulin detemir), and the safety distinction between FDA-approved oral peptides and the wave of unverified products. The piece sits alongside the AMA's late-April primer on injectable peptides and STAT, Scientific American, Washington Post, and ABC News coverage from earlier in the year — collectively building the public-facing safety narrative ahead of the July 23–24 PCAC meeting. The FAQ explicitly flags the FDA expert-panel review and the gap between Category 2 removal and FDA approval.

#ajmc #oral-peptides #bioavailability #consumer-education #pcac #snac
Regulatory

State-Level Peptide Compounding Enforcement Diverges Sharply: California Board 30+ Actions Since 2023, Texas More Permissive for Licensed 503A Operations

FormBlends and the FDA Law Blog 'Pep(tide) Rally' analyses surfaced a state-level compliance map that compounders are now navigating ahead of the July PCAC. California's Board of Pharmacy has issued 30+ enforcement actions against peptide-compounding pharmacies since 2023, scrutinizing both quality and technical regulatory compliance. Texas Board of Pharmacy enforcement has historically focused on egregious quality violations rather than minor technical issues, making the state more accessible for licensed 503A and 503B operations under physician prescription. The gap matters because telehealth platforms route fulfillment through state-by-state pharmacy networks; a CVS or compounder routing decision in 2026 is now a state-policy decision as much as a federal one.

#state-compounding #california #texas #503a #peptide-policy #pharmacy-board
Research

bioRxiv (May 1): Generative AI Designs Peptides with Custom Secondary Structure Motifs Using Reduced Amino-Acid Alphabets

A May 1 bioRxiv preprint introduces a generative AI protein-design model trained on hundreds of thousands of structures from the RCSB PDB to produce peptides with custom secondary structure motifs while operating on reduced amino-acid alphabets. The work targets a real bottleneck in cyclic peptide drug development — generating sequences that fold into specified secondary-structure scaffolds without exhausting the full 20-letter design space, which lowers the barrier for synthesis and downstream maturation. It joins the recent University of Utah PapB enzymatic cyclization paper, the Nature Communications few-shot AI Acinetobacter pipeline, and Profluent's recombinase work as part of the broader AI-peptide-design wave through April–May 2026.

#ai-peptide-design #generative-ai #biorxiv #secondary-structure #cyclic-peptides #protein-design
Industry

TIDES USA 2026 Conference Set for May 11–14 Boston, Featuring Bachem, Gilead, Novo Nordisk on Peptide and Oligonucleotide CMC + GMP Capacity

TIDES USA 2026 — the year's leading oligo, peptide, and mRNA therapeutics conference — opens May 11–14 in Boston, with six concurrent scientific tracks and 200+ presentations. Programmatic highlights include CMC strategy for complex dual and triple agonists under regulatory scrutiny, defining defensible starting materials for GLP-1 APIs, and how CDMOs are securing scarce GMP suite capacity dominated by big-pharma volume contracts. Bachem, PolyPeptide, CordenPharma, Gilead, and Novo Nordisk teams are scheduled to speak — the same week as Hims & Hers' Q1 print and within the new AJMC oral-peptides public-facing news cycle.

#tides-usa-2026 #peptide-cdmo #manufacturing #bachem #gilead #novo-nordisk #boston
Industry

Hims & Hers May 11 Q1 2026 Print Preview: $600–625M Revenue Guide, Testosterone Rx+ Diversifies Beyond GLP-1, Peptide Manufacturing Pivot Looms Post-PCAC

Hims & Hers reports Q1 2026 results May 11 after market close. Company guidance: $600–625M revenue (2–7% YoY) and $35–55M adjusted EBITDA (~7% margin), with Q1 carrying a roughly $65M timing impact from the weight-loss shift to 503A fulfillment. Outlook (ex-Eucalyptus) is $2.7–2.9B revenue and $300–375M EBITDA. Hims also launched Testosterone Rx+ — a once-daily pill for low-libido idiopathic hypogonadism — as a non-GLP-1 specialty addition, signaling the wider longevity and peptide play the company has telegraphed for 2026. The California peptide-manufacturing facility acquired in February 2025 sits as a post-PCAC option for producing reclassified Category 1 peptides if the July meeting clears the path.

#hims-hers #q1-2026 #testosterone-rx #longevity #peptide-manufacturing #telehealth